{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-198777","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2025-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.025628+00:00","generated_at":"2026-05-17T07:20:16.773607+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Chief Medical Officer Hetal Kocinsky departs; Andrew King to lead clinical programs","bullets":["Hetal Kocinsky, M.D., left CMO role effective Sept 9, 2025.","Company expects separation agreement: 12 months base salary plus 12 months COBRA premium payment.","Dr. Andrew King, Ph.D, CSO & Head of R&D, will continue leading scientific and clinical programs.","No successor named for CMO role; no details on search process."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-198777","json":"https://secwatch.observer/filing/0001193125-25-198777.json","markdown":"https://secwatch.observer/filing/0001193125-25-198777.md","text":"https://secwatch.observer/filing/0001193125-25-198777.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000119312525198777/0001193125-25-198777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000119312525198777/d116486d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:20:16.773607+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}